Small Molecule Deals Up 7000% in 2026 — Here's the Data

Seventy small molecule deals closed between March 29 and September 29, 2026 — up from exactly zero in the preceding six-month window. That's a 7000% increase, and it's the single largest modality-level surge Ambrosia has tracked this year. The driver isn't nostalgia for chemistry; it's a structural recalibration by Big Pharma BD teams who spent 2024–2025 chasing biologics and cell therapies, watched those pipelines stall in the clinic, and are now backfilling with oral, CNS-penetrant, and targeted degrader assets that can actually hit Phase III timelines.

The Data — Small Molecule Deal Activity, Period over Period

The zero in the prior period demands context. It reflects a combination of deal-timing noise and a genuine lull in small molecule licensing 2026 Q1 — BD teams were digesting large biologics transactions closed in late 2025 and waiting for IRA pricing clarity on oral drugs in Medicare Part D. Once CMS published its expanded negotiation list in February 2026 and the market absorbed the pricing floor reality, capital rotated hard back into chemistry-driven modalities where margin profiles, despite government price pressure, remain superior to most biologic categories on a risk-adjusted basis.

What's Driving the Trend

Three forces converged to produce this surge in small molecule deal trends 2026:

1. Pipeline gaps are real, and they're chemistry-shaped. Merck faces a $15B+ revenue cliff as KEYTRUDA biosimilar competition approaches. Roche needs to replace aging franchises in oncology and neuroscience. Both signed significant small molecule deals in September 2026 — Merck with SciBrunch Therapeutics ($400M upfront, $2.13B TDV) and Roche with Atavistik Bio ($70M upfront, $2B TDV). These aren't exploratory option deals. These are conviction bets on clinical-stage or late-preclinical oral assets that can reach the market before patent cliffs hit. The urgency is palpable in the deal structures: upfronts are running at 19–20% of total deal value, well above the 12–15% range that characterized 2024 small molecule transactions tracked in our Deal Benchmarks.

2. AI-designed chemistry is finally producing licensable assets. The 2022–2024 wave of AI-drug-design hype generated skepticism — rightly so. But several platforms have now advanced AI-originated small molecules into IND-enabling studies with differentiated selectivity profiles and clean tox packages. Licensors like SciBrunch and Atavistik represent this new generation: computationally designed compounds with enough preclinical validation to command nine-figure upfronts. Pharma BD teams, burned by overpriced platform deals in 2023, are now comfortable paying real money for specific assets that emerged from these platforms rather than broad access agreements.

3. Oral delivery is winning the formulary war. Payers, PBMs, and IDNs have made it abundantly clear through 2025–2026 formulary decisions that they prefer oral therapies where clinical equivalence exists. The GLP-1 oral race, the shift toward oral PCSK9 inhibitors, and growing demand for oral biologics alternatives have refocused pharma BD on small molecules that can serve as first-line or maintenance therapies in crowded indications. This isn't a fad — it's a structural preference embedded in reimbursement policy, and it's making licensable oral assets dramatically more valuable.

Notable Deals

The SciBrunch-Merck deal is the headline grabber and it should be. A $400M upfront for a small molecule asset — likely a targeted protein degrader or allosteric inhibitor based on SciBrunch's disclosed platform — puts this in the top decile of upfront payments for pre-Phase III small molecules over the last five years. The $2.13B total deal value signals Merck's expectation that this asset addresses a large-market indication, probably oncology or immunology. Run this through the Ambrosia calculator and the upfront-to-TDV ratio of 18.8% is aggressive but rational given Merck's timeline pressure.

Atavistik Bio's deal with Roche is equally revealing but for different reasons. The $70M upfront against a $2B TDV means Roche is paying a 3.5% upfront ratio — classic early-stage deal economics with heavy milestone loading. The gap between this structure and Merck's SciBrunch terms tells you everything about stage-dependent pricing power. If you're a biotech founder holding a Phase I–ready small molecule with clean IND-enabling data, you should be pricing off the SciBrunch comp, not the Atavistik comp. Stage is worth 4–5x in upfront leverage right now.

The Psyence Labs–Texas Ibogaine Research Corporation deal and the AFT–Mikasa Seiyaku transaction represent the long tail: smaller, geographically specific licensing agreements that collectively account for much of the 70-deal count. Undisclosed financial terms on these deals likely mean sub-$20M TDVs. They matter because they show breadth — small molecule licensing 2026 isn't limited to oncology mega-deals. CNS (psychedelics, neuroscience), specialty pharma, and Asia-Pacific regional licensing are all active channels.

What This Means for BD Teams Right Now

If you're selling: This is a seller's market, but it won't last. The surge from zero to 70 means pent-up demand is being released, not that a new sustainable plateau has been established. Use the next 90 days to run competitive processes. If you have clinical-stage oral assets in oncology, immunology, or cardiometabolic disease, you should be getting term sheets from at least three pharma partners simultaneously. Upfronts above 15% of TDV are achievable for differentiated assets — push for it. Reference the SciBrunch comp explicitly in your term sheet discussions.

If you're buying: Move now but structure defensively. Milestone-heavy deals like Roche–Atavistik are the right template for preclinical assets. Don't pay SciBrunch-level upfronts unless you have Phase I data in hand and a clear line of sight to a registrational endpoint. The biggest risk is overpaying in a frenzy and then watching IRA-driven price compression erode peak sales projections. Build pricing scenario analysis into every deal model — our Deal Benchmarks database includes post-IRA adjusted peak sales multiples that should be your baseline.

Deal structures gaining favor: Opt-in/opt-out structures with decision gates at Phase I data readout. Co-development agreements where the biotech retains US rights and licenses ex-US. Upfront equity stakes (5–15% positions) as a partial substitute for cash upfronts — this is particularly common in deals with sub-$50M upfronts where the licensor prefers alignment over liquidity.

Deal structures losing favor: Broad platform access deals. Pharma is done paying $100M+ for the right to nominate targets from an AI platform. They want specific assets, specific indications, specific timelines. If your BD deck leads with "platform," rewrite it to lead with "asset."

Benchmark your deal against current market rates. Whether you're structuring an upfront, negotiating milestone schedules, or modeling royalty tiers, use the Ambrosia calculator to pressure-test your terms against 2026 small molecule comps in real time.